Sanofi, which manufactures vaccines through its unit Sanofi-Pasteur, said the vaccine doses required to be based on clinical trials that will be made during the summer in the northern hemisphere.
The announcement was made while the company was heading to a meeting of the Advisory Committee on Immunization Practices, which was responsible for advising the Centers for Disease Control and Prevention United States (CDC, for its initials in English).
Sanofi has said that it manufactures 40 percent of the global immunization against influenza, said it will continue to develop the vaccine against seasonal influenza for the flu season 2009/2010 in the northern hemisphere, as recommended by the World Health Organization (WHO).
The production of seasonal influenza vaccine in the Northern Hemisphere and Southern Hemisphere remains a priority, said the company.
Seasonal flu kills between 250,000 and 500,000 people a year.
The company also said that, working at maximum capacity The Pennsylvania plant can produce 150 million doses a year to fight seasonal influenza. French plant can produce 120 million doses a year, he said.
The government has pledged billions of dollars to combat the H1N1 influenza. 1000 United States has set aside millions of dollars. The Netherlands asked for an order of 34 million doses and Australia 10 million requested, while the WHO declared pandemic influenza H1N1.
Other companies are producing vaccines Novartis AG, Baxter International Inc , GlaxoSmithKline and Solvay.
(Reporting by Julie Steenhuysen; Edited by Javier Leira in Spanish)
Post a Comment